Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21756730 | 0.81 | NPC1 (0.52) | LMNAMAPT | |
| SCHEMBL21756726 | 0.81 | NPC1 (0.52) | LMNAMAPT | |
| SCHEMBL21756727 | 0.81 | NPC1 (0.52) | LMNAMAPT | |
| SCHEMBL31469580 | 0.78 | HTT (0.49) | SMN1; SMN2ADORA2AALPLCNR1LMNA | |
| SCHEMBL23881925 | 0.77 | MAPT (0.50) | CNR1LMNAMAPT | |
| SCHEMBL21756731 | 0.77 | MAPT (0.50) | CNR1LMNAMAPT | |
| SCHEMBL16383898 | 0.76 | L3MBTL1 (0.58) | SMN1; SMN2LMNAMAPTL3MBTL1 | |
| SCHEMBL9089575 | 0.76 | ALDH1A1 (0.51) | SMN1; SMN2RECQLTSHRLMNAMAPT | |
| SCHEMBL8995482 | 0.76 | — | — | |
| SCHEMBL15118711 | 0.76 | FFAR1 (0.32) | SMN1; SMN2RECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104877001-B | Antifungal formulations | 西尼克斯公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-2326172-B1 | ANTIFUNGAL AGENTS | SCYNEXIS INC (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2326172-B1 | ANTIFUNGAL AGENTS | SCYNEXIS INC (US) | 2014-10-22 | — | — | EP | disclosed |
| US-8188085-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188085-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188085-B2 | Antifungal agents | MERCK SHARP & DOHME CORP. (US) | 2012-05-29 | — | — | US | disclosed |
| CN-102176827-A | Antifungal formulations | MERCK SHARP & DOHME | 2011-09-07 | — | — | CN | disclosed |
| EP-2326172-A1 | ANTIFUNGAL AGENTS | Merck Sharp & Dohme Corp. (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2326181-A1 | ANTIFUNGAL AGENTS | Merck Sharp & Dohme Corp. (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2010019203-A1 | ANTIFUNGAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019203-A1 | ANTIFUNGAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019204-A1 | ANTIFUNGAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019204-A1 | ANTIFUNGAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113439-A1 | Antifungal agents | GMDS, GBA3, UGGT1 | SMN1; SMN2 3768/4885ADORA3 1249/4885ADORA2A 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.